Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
Immunotherapy98 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A00062 | 35235789 | Cell Rep | Distinct hepatic immunological patterns are associated with the progression or inhibition of hepatocellular carcinoma. | 2022 | Details |
| A00765 | 34975333 | Int J Biol Sci | Implication of the hepatokine, fibrinogen-like protein 1 in liver diseases, metabolic disorders and cancer: The need to harness its full potential. | 2022 | Details |
| A00941 | 34923459 | Wiad Lek | THE EFFECTIVENESS OF COMPLEX THERAPY WITH THE INCLUSION OF THE URSODEOXYCHOLIC ACID IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE IN COMBINATION WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE. | 2021 | Details |
| A01058 | 34884762 | Int J Mol Sci | Steatosis, Steatohepatitis and Cancer Immunotherapy: An Intricate Story. | 2021 | Details |
| A01952 | 34555422 | J Hepatol | NAFLD-driven HCC: Safety and efficacy of current and emerging treatment options. | 2021 | Details |
| A02478 | 34359642 | Cancers (Basel) | The Emerging Factors and Treatment Options for NAFLD-Related Hepatocellular Carcinoma. | 2021 | Details |
| A02834 | 34225438 | Zhonghua Gan Zang Bing Za Zhi | [Mechanism of T lymphocyte subsets in the malignant transformation of non-alcoholic fatty liver disease]. | 2021 | Details |
| A03078 | 34139486 | ESMO Open | Cancer and hepatic steatosis. | 2021 | Details |
| A03831 | 33854987 | J Hepatocell Carcinoma | NAFLD-Associated HCC: Progress and Opportunities. | 2021 | Details |
| A04094 | 33762733 | Nature | NASH limits anti-tumour surveillance in immunotherapy-treated HCC. | 2021 | Details |
| A04176 | 33727658 | Commun Biol | Adiponectin-expressing Treg facilitate T lymphocyte development in thymic nurse cell complexes. | 2021 | Details |
| A04564 | 33578800 | Cancers (Basel) | Inflammatory Mechanisms Underlying Nonalcoholic Steatohepatitis and the Transition to Hepatocellular Carcinoma. | 2021 | Details |
| A04691 | 33541087 | Chin Clin Oncol | Epidemiology, mutational landscape and staging of hepatocellular carcinoma. | 2021 | Details |
| A04770 | 33511275 | Clin Exp Hepatol | Epidemiology of non-alcoholic fatty liver disease and risk of hepatocellular carcinoma progression. | 2020 | Details |
| A06092 | 33010248 | Gastroenterology | Steatohepatitis Impairs T-cell-Directed Immunotherapies Against Liver Tumors in Mice. | 2020 | Details |
| A07008 | 32660172 | Zhonghua Gan Zang Bing Za Zhi | [Carcinoembryonic type specific markers and liver cancer immunotherapy]. | 2020 | Details |
| A07009 | 32660170 | Zhonghua Gan Zang Bing Za Zhi | [Strategies and challenges of immunotherapy for hepatocellular carcinoma]. | 2020 | Details |
| A07354 | 32527116 | Chin Clin Oncol | Hepatocellular carcinoma, novel therapies on the horizon. | 2020 | Details |
| A07372 | 32523311 | World J Gastroenterol | Role of γδT cells in liver diseases and its relationship with intestinal microbiota. | 2020 | Details |
| A08875 | 31954491 | J Hepatol | Advances in resection and transplantation for hepatocellular carcinoma. | 2020 | Details |
| A08877 | 31954488 | J Hepatol | Gut microbiome in HCC - Mechanisms, diagnosis and therapy. | 2020 | Details |
| A09878 | 31577913 | FASEB J | Imaging inflammation and its resolution in health and disease: current status, clinical needs, challenges, and opportunities. | 2019 | Details |
| A10449 | 31333307 | World J Gastroenterol | Hepatocellular carcinoma: Therapeutic advances in signaling, epigenetic and immune targets. | 2019 | Details |
| A10548 | 31293335 | World J Gastroenterol | Immunotherapy for hepatocellular carcinoma: Current and future. | 2019 | Details |
| A10594 | 31278269 | Nat Commun | Relaxin gene delivery mitigates liver metastasis and synergizes with check point therapy. | 2019 | Details |
| A10838 | 31164564 | Methods Protoc | Establishment of Orthotopic Liver Tumors by Surgical Intrahepatic Tumor Injection in Mice with Underlying Non-Alcoholic Fatty Liver Disease. | 2018 | Details |
| A11826 | 30719457 | J Immunol Res | The Crosstalk between Fat Homeostasis and Liver Regional Immunity in NAFLD. | 2019 | Details |
| A11903 | 30687560 | Precis Clin Med | New insights into the pathogenesis and treatment of non-viral hepatocellular carcinoma: a balancing act between immunosuppression and immunosurveillance. | 2018 | Details |
| A13029 | 30173562 | Expert Opin Biol Ther | Fecal microbiota transplantation: a promising strategy in preventing the progression of non-alcoholic steatohepatitis and improving the anti-cancer immune response. | 2018 | Details |
| A13546 | 29920654 | Clin Exp Immunol | Immunotherapy with oral administration of humanized anti-CD3 monoclonal antibody: a novel gut-immune system-based therapy for metaflammation and NASH. | 2018 | Details |
| A13715 | 29795111 | Cell Death Dis | Carnitine palmitoyltransferase gene upregulation by linoleic acid induces CD4+ T cell apoptosis promoting HCC development. | 2018 | Details |
| A14229 | 29514661 | J Transl Med | Physiological and molecular effects of interleukin-18 administration on the mouse kidney. | 2018 | Details |
| A14973 | 29150490 | Gut | Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma. | 2017 | Details |
| A17184 | 27923447 | Metabolism | Amelioration of non-alcoholic fatty liver disease with NPC1L1-targeted IgY or n-3 polyunsaturated fatty acids in mice. | 2016 | Details |
| A17320 | 27848888 | Curr Drug Metab | Immunotherapy in Liver Diseases: A Balance Between Immunity and Tolerance. | 2016 | Details |
| A17376 | 27818591 | World J Gastroenterol | Oral administration of a non-absorbable plant cell-expressed recombinant anti-TNF fusion protein induces immunomodulatory effects and alleviates nonalcoholic steatohepatitis. | 2016 | Details |
| A17460 | 27778363 | Aliment Pharmacol Ther | Review article: novel methods for the treatment of non-alcoholic steatohepatitis - targeting the gut immune system to decrease the systemic inflammatory response without immune suppression. | 2016 | Details |
| A19313 | 26634783 | Expert Rev Gastroenterol Hepatol | The role of immune mechanisms in alcoholic and nonalcoholic steatohepatitis: a 2015 update. | 2015 | Details |
| A20574 | 25876706 | J Clin Immunol | Oral Administration of OKT3 MAb to Patients with NASH, Promotes Regulatory T-cell Induction, and Alleviates Insulin Resistance: Results of a Phase IIa Blinded Placebo-Controlled Trial. | 2015 | Details |
| A23037 | 24084730 | Int J Mol Sci | Immunological mechanisms in the pathophysiology of non-alcoholic steatohepatitis. | 2013 | Details |
| A23829 | 23442833 | J Clin Gastroenterol | Immune therapy for nonalcoholic steatohepatitis: are we there yet? | 2013 | Details |
| A25026 | 22236001 | Clin Exp Immunol | Oral administration of immunoglobulin G-enhanced colostrum alleviates insulin resistance and liver injury and is associated with alterations in natural killer T cells. | 2012 | Details |
| A28612 | 35235346 | Sci Adv | Clinically translatable cytokine delivery platform for eradication of intraperitoneal tumors. | 2022 | Details |
| A28719 | 35096290 | Iran J Basic Med Sci | Game theory applications in host-microbe interactions toward disease manifestation: Mycobacterium tuberculosis infection as an example. | 2021 | Details |
| A28741 | 35076948 | Hepatology | Therapeutic efficacy of FASN inhibition in preclinical models of HCC. | 2022 | Details |
| A28835 | 34923550 | Curr Opin Oncol | Immunomodulation for hepatocellular carcinoma therapy: current challenges. | 2022 | Details |
| A28901 | 34847382 | ESMO Open | Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib. | 2021 | Details |
| A29034 | 34670284 | Dtsch Med Wochenschr | [Hepatocellular Carcinoma]. | 2021 | Details |
| A29083 | 34606522 | JMIRx Med | Early Experience With Neutralizing Monoclonal Antibody Therapy for COVID-19: Retrospective Cohort Survival Analysis and Descriptive Study. | 2021 | Details |
| A29137 | 34520619 | Hepatol Res | Does immune checkpoint inhibitor exhibit limited efficacy against non-viral hepatocellular carcinoma?: A review of clinical trials. | 2021 | Details |
| A29177 | 34464283 | IEEE Trans Cybern | Optimal Regulation Strategy for Nonzero-Sum Games of the Immune System Using Adaptive Dynamic Programming. | 2021 | Details |
| A29599 | 33815418 | Front Immunol | Hepatocellular Carcinoma Immune Landscape and the Potential of Immunotherapies. | 2021 | Details |
| A29604 | 33811045 | Cancer Discov | T-cell Dysfunction Limits Immunotherapy Efficacy in NASH-Induced Liver Cancer. | 2021 | Details |
| A30206 | 32808760 | Acc Chem Res | Nanoscale Metal-Organic Frameworks for Cancer Immunotherapy. | 2020 | Details |
| A30789 | 31779702 | J Immunother Cancer | Immunotherapy response evaluation with magnetic resonance elastography (MRE) in advanced HCC. | 2019 | Details |
| A31654 | 30102778 | Hepatology | Characteristics of Immune Response to Tumor-Associated Antigens and Immune Cell Profile in Patients With Hepatocellular Carcinoma. | 2018 | Details |
| A32383 | 28593566 | Mol Cell Biochem | Cellular and molecular targets for the immunotherapy of hepatocellular carcinoma. | 2017 | Details |
| A32800 | 27457348 | Rev Recent Clin Trials | Hepatocellular Carcinoma in Alcoholic Liver Disease: Current Management and Recent Advances. | 2016 | Details |
| A33687 | 25412903 | J Viral Hepat | Oral anti-CD3 immunotherapy for HCV-nonresponders is safe, promotes regulatory T cells and decreases viral load and liver enzyme levels: results of a phase-2a placebo-controlled trial. | 2014 | Details |
| A35675 | 19938191 | World J Gastroenterol | Immunotherapy for nonalcoholic steatohepatitis using the multiple cytokine production modulator Y-40138. | 2009 | Details |
| A37764 | 14720457 | Curr Gastroenterol Rep | Advances in alcoholic liver disease. | 2004 | Details |
| A37790 | 14652850 | Biol Blood Marrow Transplant | Adoptive immunotherapy to increase the level of donor hematopoietic chimerism after nonmyeloablative marrow transplantation for severe canine hereditary hemolytic anemia. | 2003 | Details |
| A42483 | 34414117 | Liver Cancer | Impaired Response to Immunotherapy in Non-Alcoholic Steatohepatitis-Related Hepatocellular Carcinoma? | 2021 | Details |
| A42584 | 34112767 | Signal Transduct Target Ther | The paradox of immunotherapy in NASH-HCC. | 2021 | Details |
| A42636 | 33948024 | Nat Rev Gastroenterol Hepatol | T cells in NASH and liver cancer: pathology and immunotherapy. | 2021 | Details |
| A42876 | 33235387 | Cell Mol Immunol | Immunobiology and immunotherapy of HCC: spotlight on innate and innate-like immune cells. | 2020 | Details |
| A43584 | 31352386 | BMJ Case Rep | Treatment of inoperable hepatocellular carcinoma with immunotherapy. | 2019 | Details |
| A43979 | 30251463 | Hepatology | Intrahepatic Cholangiocarcinoma: Continuing Challenges and Translational Advances. | 2019 | Details |
| A44268 | 29192212 | Nat Rev Cancer | Immunotherapy: Burning fences. | 2017 | Details |
| A45129 | 25993176 | Am Soc Clin Oncol Educ Book | Hepatocellular carcinoma tumor board: making sense of the technologies. | 2015 | Details |
| A47673 | 33864004 | Cell Mol Immunol | Inflammatory processes in the liver: divergent roles in homeostasis and pathology. | 2021 | Details |
| A47697 | 33537099 | Theranostics | Immunotherapy for targeting cancer stem cells in hepatocellular carcinoma. | 2021 | Details |
| A47711 | 33159158 | Cell Mol Immunol | Neutrophils in liver diseases: pathogenesis and therapeutic targets. | 2020 | Details |
| A47720 | 32974761 | Abdom Radiol (NY) | Effect of sarcopenia on systemic targeted therapy response in patients with advanced hepatocellular carcinoma. | 2020 | Details |
| A47762 | 32340652 | Gene Expr | Immune Checkpoint Inhibitors in Hepatocellular Cancer: Current Understanding on Mechanisms of Resistance and Biomarkers of Response to Treatment. | 2020 | Details |
| A47781 | 32021262 | Onco Targets Ther | Programmed Cell Death Protein-1 (PD-1)-Targeted Immunotherapy for Advanced Hepatocellular Carcinoma in Real World. | 2020 | Details |
| A47958 | 28128716 | Immunotherapy | Immunosuppression strategies in liver transplantation patient; patients with hepatocellular carcinoma. | 2017 | Details |
| A48540 | 34430534 | Hepatobiliary Surg Nutr | Lack of response to immunotherapy in non-alcoholic steatohepatitis related hepatocellular carcinoma. | 2021 | Details |
| A48588 | 33540870 | Cancers (Basel) | Clinical Characterisation and Management of the Main Treatment-Induced Toxicities in Patients with Hepatocellular Carcinoma and Cirrhosis. | 2021 | Details |
| A48590 | 33479224 | Nat Rev Dis Primers | Hepatocellular carcinoma. | 2021 | Details |
| A48602 | 33235462 | Onco Targets Ther | Adverse Effects of Immune-Checkpoint Inhibitors in Hepatocellular Carcinoma. | 2020 | Details |
| A48626 | 32747413 | Gut | Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups. | 2020 | Details |
| A48641 | 32582143 | Front Immunol | The Genus Alistipes: Gut Bacteria With Emerging Implications to Inflammation, Cancer, and Mental Health. | 2020 | Details |
| A48724 | 30652433 | J Med Imaging Radiat Oncol | Outcome and safety of targeted liver biopsies for indeterminate lesions in patients with chronic liver disease: A single centre experience. | 2019 | Details |
| A48735 | 30319645 | Front Immunol | Inflammasome: A Double-Edged Sword in Liver Diseases. | 2018 | Details |
| A48781 | 28987386 | Cancer Lett | Autophagy in the "inflammation-carcinogenesis" pathway of liver and HCC immunotherapy. | 2017 | Details |
| A48798 | 28392436 | J Immunol Methods | An oral administration of a recombinant anti-TNF fusion protein is biologically active in the gut promoting regulatory T cells: Results of a phase I clinical trial using a novel oral anti-TNF alpha-based therapy. | 2017 | Details |
| A49433 | 35750137 | J Hepatol | Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease - novel insights into cellular communication circuits. | 2022 | Details |
| A49755 | 35646285 | World J Gastrointest Oncol | Gut microbiome in non-alcoholic fatty liver disease associated hepatocellular carcinoma: Current knowledge and potential for therapeutics. | 2022 | Details |
| A49773 | 35642526 | Expert Opin Emerg Drugs | Emerging drugs for the treatment of hepatocellular carcinoma. | 2022 | Details |
| A50469 | 35378172 | J Hepatol | Metformin treatment rescues CD8+ T-cell response to immune checkpoint inhibitor therapy in mice with NAFLD. | 2022 | Details |
| A50777 | 35269846 | Int J Mol Sci | PD-1/PD-L1 Immuno-Mediated Therapy in NAFLD: Advantages and Obstacles in the Treatment of Advanced Disease. | 2022 | Details |
| A51341 | 35477865 | Gut | Immature neutrophils bring anti-PD-1 therapy in NASH-HCC to maturity. | 2022 | Details |
| A51342 | 35477863 | Gut | CXCR2 inhibition enables NASH-HCC immunotherapy. | 2022 | Details |
| A51346 | 35432597 | Therap Adv Gastroenterol | Frontline therapy for advanced hepatocellular carcinoma: an update. | 2022 | Details |
| A51407 | 35754339 | Antioxid Redox Signal | Emerging insights on immunotherapy in liver cancer. | 2022 | Details |
| A51458 | 34567824 | Liver Res | Overexpression of Galectin-1 and Galectin-3 in hepatocellular carcinoma. | 2020 | Details |
| A51939 | 33073617 | Nutr Cancer | Herbal and Natural Dietary Products: Upcoming Therapeutic Approach for Prevention and Treatment of Hepatocellular Carcinoma. | 2020 | Details |